Topic: Product Liability

Legal analysts compare the current litigation against tech giants to the 1990s reckoning of the Big Tobacco industry. By focusing on "behavior modification by design" rather than content, plaintiffs' lawyers are successfully bypassing Section 230 and First Amendment protections. Fears are rising within Silicon Valley that these precedents will soon extend to AI chatbots and other addictive digital products.

Ozempic is facing over 2,000 lawsuits alleging that the manufacturer downplayed severe side effects, including blindness and intestinal issues. Legal experts are now calculating damages for physical harm, emotional distress, and lost wages for affected users.

Legal experts discuss a potential strategy by the Trump administration to use Tylenol litigation as a "workaround" to challenge vaccine manufacturer immunity. Because Tylenol does not have the same statutory immunity as vaccines, lawsuits in federal court could force discovery regarding how acetaminophen interacts with vaccinations. This could publicly expose data on vaccine safety and potentially lead to the rescinding of the 1986 Vaccine Injury Act's protections.

A discussion regarding the legal protections for vaccine manufacturers highlights the lack of liability for adverse reactions as a primary driver of industry profits. Historical examples, including the 1976 swine flu vaccine and the 2006 HPV vaccine rollout, are cited as instances where public health initiatives were allegedly prioritized over safety concerns. Critics argue that removing liability shields would force higher standards in vaccine processing.

The shortage of medical masks in the U.S. is attributed to a reliance on Chinese manufacturing, with reports that China withheld supplies during the initial outbreak. U.S. construction companies are being granted liability waivers to donate their stockpiles of N95 masks to hospitals as manufacturers retool to produce ventilators.